| Previous Close | 152.80 |
| Open | 152.00 |
| Volume | 10,346,011 |
| Avg. Volume (3M) | 12,651,070 |
| Market Cap | 138,136,780,800 |
| Price / Earnings (Forward) | 112.36 |
| Price / Sales | 43.23 |
| Price / Book | 17.73 |
| 52 Weeks Range | |
| Earnings Date | 15 Sep 2025 |
| Profit Margin | -24.23% |
| Operating Margin (TTM) | -31.62% |
| Diluted EPS (TTM) | -0.660 |
| Quarterly Revenue Growth (YOY) | 29.40% |
| Total Debt/Equity (MRQ) | 58.52% |
| Current Ratio (MRQ) | 5.15 |
| Operating Cash Flow (TTM) | -527.62 M |
| Levered Free Cash Flow (TTM) | -1.11 B |
| Return on Assets (TTM) | -4.16% |
| Return on Equity (TTM) | -8.89% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | AKESO | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| AKESO | 138 B | - | - | 17.73 |
| INNOVENT BIO | 152 B | - | - | 10.52 |
| PHARMARON | 47 B | 0.92% | 15.04 | 2.59 |
| WUXI BIO | 157 B | - | 36.15 | 3.22 |
| SINO BIOPHARM | 131 B | 0.96% | 66.64 | 4.14 |
| BEIGENE | 316 B | - | - | 9.69 |
|
Akeso Inc is an investment holding company. The Company’s subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Growth |
| % Held by Insiders | 24.58% |
| % Held by Institutions | 28.47% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |